TL;DR
Get workout gear delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
A MedPage Today neurology roundup published October 27, 2026, summarized three findings involving Alzheimer’s and dementia: research linking head shape to Alzheimer’s pathology, a prenatal phosphatidylcholine trial reporting some child outcomes through age 4, and an analysis suggesting platelet genetics may affect aspirin’s potential role in dementia prevention. The findings do not establish that head shape causes Alzheimer’s, that choline raises IQ generally, or that aspirin prevents dementia.
A MedPage Today neurology roundup published October 27, 2026, highlighted three studies on Alzheimer’s and dementia: one examining whether head shape is associated with Alzheimer’s pathology, a randomized trial of prenatal phosphatidylcholine supplementation and children’s outcomes, and an analysis suggesting that platelet-related genetic differences may affect aspirin’s potential role in dementia prevention. The summarized findings are preliminary or limited in scope and do not establish that changing head shape, taking choline, or using aspirin prevents dementia.
The roundup listed a study in Alzheimer’s & Dementia asking whether head shape may influence Alzheimer’s disease pathology. The supplied report does not describe the study design, participants, findings, or whether the researchers established a direct relationship. It therefore supports describing the work as an investigation, not as evidence that head shape causes or predicts Alzheimer’s disease.
A randomized trial reported in the American Journal of Obstetrics and Gynecology tested prenatal phosphatidylcholine supplements. The roundup says children whose mothers received the supplement had fewer social-withdrawal problems and higher IQ test performance through age 4, but attention problems did not decrease. It provides no sample size, effect estimates, dosing details, or information on longer-term outcomes.
Separately, data from the ASPREE trial, summarized in Alzheimer’s & Dementia, suggested that polygenic scores related to platelet count may influence how aspirin could affect dementia prevention. The report says this may mean some subgroups of older adults could benefit, but it does not state that aspirin was shown to prevent dementia or identify which groups might benefit. The findings are described as suggestive rather than as a treatment recommendation.
What the Findings Could Mean
Together, the three topics show how dementia research is testing links across different stages of life: possible biological associations in the brain, exposures during pregnancy, and preventive treatment in older adults. The studies could help researchers identify questions for future trials, but the brief descriptions do not provide enough evidence to change clinical practice.
For readers, the distinction between a research signal and a proven intervention matters. The choline trial reported selected outcomes through age 4, not a guarantee of lasting cognitive benefit. The aspirin analysis points to a possible difference among genetic subgroups, not a basis for starting aspirin. Aspirin can have risks, including bleeding, so decisions about its use should be made with a qualified clinician.
Products Worth Considering
Levoit Vital 100S-P Air Purifier with Washable Pre-Filter
Garmin Forerunner 570 GPS Running Smartwatch, 47mm, Aluminum, Black
Therabody Theragun Prime 6th Generation Deep Tissue Massage Gun, Navy
As an affiliate, we earn on qualifying purchases.
Three Questions Across Neurology
The October 27 report was a short roundup of neurology and neuroscience research rather than a single study announcement. It also listed developments on a U.K. Alzheimer’s platform trial, cognitive resilience, racial differences in amyloid onset, emergency care after transient ischemic attack, functional seizures, and cognitive fatigue after long COVID. The three studies discussed here were selected from that broader collection.
The report identifies journals and summarizes headline findings, but does not provide links to the individual study details beyond the overall MedPage Today article. In particular, the head-shape item is presented as a research question, while the prenatal supplement and aspirin items include brief descriptions of reported results. Those differences limit how directly the findings can be compared.
“Can head shape influence Alzheimer’s disease pathology?”
— MedPage Today roundup, summarizing the head-shape research
What the Summaries Leave Open
The source does not give the head-shape study’s methods or results, so it is unclear whether researchers found an association, what measures they used, or how strong any relationship was. The brief account also does not establish whether the finding applies across populations or has any value for predicting individual risk.
For the prenatal trial, the number of participants, supplement dose, size of the reported differences, and potential limitations are not included. Follow-up is described only through age 4, leaving later cognitive and social outcomes unknown. For the aspirin analysis, the report does not identify the genetic subgroups, state whether the finding was confirmed in a separate population, or show that taking aspirin reduced dementia incidence. None of these summaries alone supports personal medical decisions.
Evidence Needed Before Advice Changes
The next step is to examine the full papers for study design, participant characteristics, measured outcomes, and statistical results. Researchers would need further evidence to determine whether the head-shape question reflects a reproducible association and whether it has clinical relevance.
The child outcomes require longer follow-up and replication to assess how durable the reported differences are. The aspirin finding would need confirmation in additional analyses or trials that specify relevant genetic groups and weigh possible benefits against harms. Until that evidence is available, the roundup offers research developments, not new guidance to use supplements or aspirin.
Key Questions
Did the report show that head shape causes Alzheimer’s disease?
No. It described a study asking whether head shape may influence Alzheimer’s pathology, but the supplied summary does not report a causal finding or enough study details to establish an association.
What did the prenatal phosphatidylcholine trial report?
The roundup says the randomized trial found fewer social-withdrawal problems and higher IQ test performance in children through age 4, with no reduction in attention problems. It does not provide effect sizes or longer-term results.
Does this research mean pregnant people should take choline supplements?
The summary is not a general supplement recommendation. It omits important trial details, and people who are pregnant or considering supplements should discuss their circumstances with a qualified health professional.
Does the aspirin analysis show that aspirin prevents dementia?
No. It suggests platelet-related genetic scores may affect aspirin’s potential impact in some groups, but the supplied report does not say aspirin was proven to prevent dementia or identify who might benefit. Aspirin use should be discussed with a clinician because it can cause harm, including bleeding.
Source: medpagetoday.com
